Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
NVDA -0.4EWJ 0.37TECK.B.TO -2.09CNQ.TO 0.71HHL.TO 0.075SYLD 0.03HAC.TO 0.04TRU -0.01
Abbott Labs (ABT)
The ultimate 360° Tracker Your financial life in one place, automatically

NYSE:ABT

Abbott Labs (ABT)

88.59
+0.18 (0.20%)
as of Jun 18, 2026, 11:52:08 pm Market Open.
234 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
COMMENT

Abbott Labs(ABT)

Jan 17, 2022
An advisor could help the caller decide whether to hold or sell some. He doesn't own either The devices made by Abbott show promise for the stock so there is upside. The pharmaceutical side is not of particular interest. These are relatively defensive stocks but market could gravitate to cyclicals.
Photo of David FingoldDavid FingoldUnlock Rating
$128.16

Stock price when the opinion was issued

$88.59

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

Nov 05, 2021
A Covid play, but he expects America to still be using their Covid testing kits for a long while to come despite medical breakthroughs.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad Money
Owned
Unlock Rating
$124.37

Stock price when the opinion was issued

$88.59

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

Oct 15, 2021
They report Wednesday. They warned of an earnings shortfall. They created a fast Covid test--great news--but then Delta hit those test sales. He's long owned this. He likes their great medical devices.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad Money
Owned
Unlock Rating
$117.49

Stock price when the opinion was issued

$88.59

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Abbott Labs(ABT)

Oct 13, 2021
Diversified. Generics to EMs, medical devices, diagnostics, nutritionals. Covid tests. Outlook cut in June, as demand for rapid tests dropped. Now we're seeing increases in rapid tests. Good growth in med devices and diabetic monitoring. More in the pipeline. Attractive value. Increases dividend every year. She'd buy it here. Yield is 1.53%. (Analysts’ price target is $129.74)
Photo of Christine PooleChristine Poole
Owned
Unlock Rating
$117.50

Stock price when the opinion was issued

$88.59

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

Jul 23, 2021

The pharmaceutical sector has not gone anywhere for decades. Now they are starting to act like value stocks. Owns other pharma companies like J&J and Senofi. Now is a good time to put pharma stocks to your porfolio.

Photo of Norman LevineNorman Levine
No
Unlock Rating
$120.80

Stock price when the opinion was issued

$88.59

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Abbott Labs(ABT)

Jun 16, 2021
(A Top Pick Jun 24/20, Up 29%) Recently revised guidance by 10-15% of earnings, as they saw a sharp decline in Covid testing. Still growing earnings in double digits. Medical devices and diagnostics are still doing well. Dividend is not high, but increased consistently. She's buying for new clients on this pullback.
Photo of Christine PooleChristine Poole
Owned
Unlock Rating
$110.58

Stock price when the opinion was issued

$88.59

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Abbott Labs(ABT)

Jun 15, 2021

Fine managers and company. They hold the record in raising dividends by 48 straight years. Super stable. They do diagnostics, nutrition, though spun off a business to Abbvie about 8 years ago. They trade in mid-20sx in PE, and grow by a decent 10%. Problem is this high valuation, so he'd look elsewhere in this space, Abbvie, which he owns.

Photo of Gordon ReidGordon Reid
No
Unlock Rating
$110.66

Stock price when the opinion was issued

$88.59

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Abbott Labs(ABT)

Jun 08, 2021
Two profit centres are the diagnostic testing and medical devices businesses, accounting for 75% of their operating profit. He's long liked this. Last week, they announced that their Covid-testing business has fallen off with the reopening, so shares sold off. But he sees long-term growth. It trades below 23x earnings in line with peers and market. ABT is defensive with strong growth. Offers good US exposure to healthcare. (Analysts’ price target is $123.33)
Photo of Chris BlumasChris Blumas
Owned
Unlock Rating
$108.10

Stock price when the opinion was issued

$88.59

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Abbott Labs(ABT)

Jun 04, 2021
It is trading at around 34x earnings. It hasn't done much in the last year. It is where it was last year, maybe 10% up. Compared to the rest of the market, it hasn't moved. Big pharma was out of favour a couple years ago. This has now come back into favour. It is fully valued now. Has had a wonderful run. A little expensive.
Photo of David BaskinDavid Baskin
No
Unlock Rating
$109.35

Stock price when the opinion was issued

$88.59

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

Abbott Labs(ABT)

Jun 03, 2021
(A Top Pick Oct 08/20, Up 0.3%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with ABT has triggered its stop at $109. To remain disciplined, we recommend covering the balance of the holding. Combined with the previous recommendation to cover 50% of the position, this will result in a net investment gain of 9%.
Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$109.00

Stock price when the opinion was issued

$88.59

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

May 20, 2021

ABT vs. MRK Both are great companies. ABT is the leading supplier of products to the medical industry. Merck has incredible products as a global pharmaceutical company. You could hold either.

Photo of Bruce MurrayBruce MurrayUnlock Rating
$117.66

Stock price when the opinion was issued

$88.59

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

May 19, 2021

ABT vs. JNJ Healthcare is in a more defensive space, moving up during the pandemic. Likes both. JNJ has a fairly nice dividend at 2.5%. 18x forward earnings for 8% growth. Performing decently, but underperforming the S&P. ABT is more in medical devices. Marginally underperforming since last March. 22x earnings with a higher growth rate of 14%. Bit more torque with ABT, and they're also in the Covid detection space. If he had to choose, it would be ABT.

Photo of Stan WongStan WongUnlock Rating
$116.21

Stock price when the opinion was issued

$88.59

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Abbott Labs(ABT)

May 18, 2021
A diversified US healthcare company in diagnostics, branded pharmaceuticals, nutrition and medical devices. It produces a lot of Covid-testing kits, which has boosted their bottom line. They can maintain double-digit earnings growth based on growth in medical devices. For instance, a diagnostic kit for diabetes (don't need to prick finger) is popular. About 40% of products are sold in emerging markets. They increase their dividend annually, for the past 49 years. Pays a 1.5% dividend. This has pulled back, so buy now. (Analysts’ price target is $133.26)
Photo of Christine PooleChristine Poole
Owned
Unlock Rating
$117.63

Stock price when the opinion was issued

$88.59

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

Apr 16, 2021
They report Tuesday. They've done great work with their Covid test that they will likely hit it out of the park.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$124.35

Stock price when the opinion was issued

$88.59

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
Showing 31 to 45 of 183 entries

You may also like

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

VEEV 0$153.3
WSP.TO 1.13$176.7
VRTX 0.47$452.1
OTEX.TO 0.24$29.47
CCO.TO 0.61$151.07

Today's Top Picks

NVDA -0.4$210.29
EWJ 0.37$96.63
TECK.B.T… -2.09$88.93
CNQ.TO 0.71$58.66
HHL.TO 0.075$6.865

Popular Articles

Latest Sell Signals

TD.TO 0.7$169.33
MBLY -0.03$8.43
ASAN 0.03$6.95
MODG -0.01$18.21
NVTS 0$24.02

Most Recent Experts

Stockchase Insights

Stockchase Insights

5i Research

Brian Acker, CA

Brian Acker, CA

Acker Finley Inc.

The Weekly Buzzing Stocks by Billy Kawasaki

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

David Burrows

David Burrows

Barometer Capital Management

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica